Köstler E, Pollack P, Seebacher C, Riedel H
Hautklinik des Bezirkskrankenhauses Dresden-Friedrichstadt.
Z Hautkr. 1990 Nov;65(11):1030-2, 1035.
The knowledge about the influence of chloroquine phosphate (CQ) on the iron metabolism in porphyria cutanea tarda (PCT) is still insufficient. In a study on 138 PCT patients treated with CQ, we observed decreasing serum iron concentration, transferrin saturation, and hepatic siderosis, as well as an increasing level of transferrin. After a one-year therapy with CQ, the patients showed normal porphyrinuria. Since there were no statistical correlations between the degree of hepatic siderosis and porphyrinuria, and since we repeatedly found remission of the PCT in spite of the continued existence of hepatic siderosis, the removal of iron cannot be regarded as the only principle of action in CQ therapy. In comparison with chloroquine, phlebotomy obviously has--even with regard to the iron deposits--no decisive advantages.
关于磷酸氯喹（CQ）对迟发性皮肤卟啉症（PCT）铁代谢影响的认识仍然不足。在一项对138例接受CQ治疗的PCT患者的研究中，我们观察到血清铁浓度、转铁蛋白饱和度和肝脏铁沉积减少，以及转铁蛋白水平升高。经过一年的CQ治疗后，患者的卟啉尿恢复正常。由于肝脏铁沉积程度与卟啉尿之间不存在统计学相关性，并且尽管肝脏铁沉积持续存在，我们仍多次发现PCT缓解，因此不能将铁的清除视为CQ治疗的唯一作用机制。与氯喹相比，放血疗法显然——即使在铁沉积方面——也没有决定性优势。
